Table 3.
Parameter | HIV-Uninfected
(N=90) |
HIV-Infected,
Antiretroviral -naïve (N=28) |
HIV-
Infected, on non-PI HAART (N=28) |
HIV-Infected,
on PI-HAART (N=70) |
---|---|---|---|---|
Anthropometric measurements | ||||
Body mass index, kg/m2 | 25.9 ± 0.5 | 25.7 ± 0.8 | 25.8 ± 0.7 | 24.8 ± 0.5 |
Waist circumference, cm c | 91.9 ± 1.3 | 90.2 ± 1.9 | 88.0 ± 1.8 | 88.8 ± 1.2 |
Hip circumference, cm c | 98.4 ± 1.0 | 96.1 ± 1.8 | 96.8 ± 1.5 | 94.6 ± 1.0 |
Waist-hip ratio c | 0.93 ± 0.01 | 0.93 ± 0.01 | 0.91 ± 0.01 | 0.94 ± 0.01 |
Oral glucose tolerance test | ||||
Fasting insulin level, μU/mLc | 18.7 ± 2.1 | 16.4 ± 2.2 | 17.7 ± 3.2 | 15.7 ± 1.2 |
Fasting glucose level, mg/dL | 96.5 ± 1.8 | 97.0 ± 2.2 | 98.1 ± 2.5 | 92.8 ± 1.6 |
Glucose level at 120 min, mg/dL | 118.5 ± 4.4 | 130.8 ± 7.7 | 123.4 ± 9.4 | 116.2 ± 4.8 |
HOMA-IR, μU/mL·mmol/Lc | 4.76 ± 0.65 | 4.04 ± 0.59 | 4.52 ± 0.96 | 3.67 ± 0.29 |
Impaired Fasting Glucose, N (%) | 24 (27) | 11 (39) | 9 (32) | 12 (17) |
Impaired Glucose Tolerance, N (%) | 16 (18) | 8 (29) | 2 (7) | 14 (20) |
Diabetes, N (%) | 7 (8) | 3 (11) | 2 (7) | 3 (4) |
HAART, highly active antiretroviral therapy;
Data are mean ± standard error unless otherwise indicated
Data missing for fasting insulin (n=5), waist circumference (n=4), hip circumference (n=6)